GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » 3-Year FCF Growth Rate

Chordate Medical Holding AB (OSTO:CMH) 3-Year FCF Growth Rate : 24.80% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB 3-Year FCF Growth Rate?

Chordate Medical Holding AB's Free Cash Flow per Share for the three months ended in Mar. 2024 was kr-0.02.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 24.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 40.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 9 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Chordate Medical Holding AB was 61.10% per year. The lowest was -151.30% per year. And the median was 31.70% per year.


Competitive Comparison of Chordate Medical Holding AB's 3-Year FCF Growth Rate

For the Medical Devices subindustry, Chordate Medical Holding AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's 3-Year FCF Growth Rate falls into.



Chordate Medical Holding AB 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Chordate Medical Holding AB  (OSTO:CMH) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Chordate Medical Holding AB 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Chordate Medical Holding AB (OSTO:CMH) Business Description

Traded in Other Exchanges
Address
c/o Regus, Kistagangen 20B, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines